LAF 389
Latest Information Update: 22 Oct 2002
At a glance
- Originator Novartis Oncology
- Class Antineoplastics; Azepines
- Mechanism of Action Aminopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 22 Oct 2002 Discontinued - Phase-I for Chronic lymphocytic leukaemia in Netherlands (unspecified route)
- 22 Oct 2002 Discontinued - Phase-I for Multiple myeloma in Netherlands (unspecified route)
- 22 Oct 2002 Discontinued - Phase-I for Non-Hodgkin's lymphoma in Netherlands (unspecified route)